








FIGURE S1

FIGURE S2







FIGURE S3

FIGURE S4











FIGURE S5

A



B






FIGURE S6

A



B





FIGURE S7





FIGURE S8



1 **Supplementary figure legends**

2 **Figure S1** (A) The expression of *SOAT1* in OSCC and normal paired samples. (B)
3 Kaplan-Meier curves of disease-specific survival for high and low groups of *SOAT1*
4 expression. (C) Heat map of *SOAT1* correlation with suppressive immunomodulatory
5 genes. (D) Heat map of *SOAT1* correlation with stimulatory immunomodulatory genes.
6 (E) Scatter plots of *SOAT1* correlation with stimulatory immunomodulatory genes. (F)
7 IHC staining intensity correlation analysis of *SOAT1* and *CD163* in 30 pairs of clinical
8 samples of OSCC paired with adjacent tissue. The asterisks represented the statistical
9 *p*-value (**p* < 0.05, ***p* < 0.01, ****p* < 0.001).

10

11 **Figure S2** Western Blot assay was performed to detect the protein expression level of
12 SOAT1 in four OSCC cell lines and HaCaT cell.

13

14 **Figure S3** (A) Volcano plot of differentially expressed genes in high and low groups of
15 *SOAT1* expression in TCGA-OSCC. (B) KEGG analysis of DEGs between high and
16 low expression groups. (C) The effects of overexpression and knockdown of *SOAT1* on
17 the expression of p-PI3K, PI3K, p-AKT, AKT, p-mTOR and mTOR in OSCC cells were
18 analyzed by Western Blot.

19

20 **Figure S4** (A) RT-qPCR analysis of macrophages after cultured with CM of *SOAT1*-
21 overexpressing Cal27 cell. (B) RT-qPCR analysis of pro-M2 polarization genes in
22 *SOAT1* overexpressing OSCC cells. (C) RT-qPCR analysis of pro-M2 polarization
23 genes in *SOAT1* knockdown OSCC cells. (D) ELISA assay to detect CTSK levels in
24 the supernatants of SCC-1 and Cal27 cells overexpressing *SOAT1*. (E) Flow cytometry
25 was used to assess the expression level of CD163 in macrophages after culture in
26 conditioned medium and treatment with ODN. (ODN: Odanacatib, a CTSK-specific
27 inhibitor) The asterisks represented the statistical *p*-value (ns = no significant; **p* < 0.05,
28 ***p* < 0.01, ****p* < 0.001, *****p* < 0.0001).

29

30 **Figure S5** (A) Box plot display the expression levels of 34 potential upstream

31 transcription factors in OSCC (n=330) and normal tissues (n=32) analyzed using the
32 TCGA-OSCC data. (B) Heatmap of the correlation of 22 potential upstream
33 transcription factors with *SOAT1*. The asterisks represented the statistical *p*-value (**p* <
34 0.05, ***p* < 0.01, ****p* < 0.001).

35

36 **Figure S6** (A) RT-qPCR and Western Blot were used to verify the efficiency of *ETS1*
37 overexpression and knockdown, simultaneously inspected the expression of *SOAT1*
38 after altering *ETS1* expression. (B) Prediction of *ETS1* binding sites in the promoter
39 region of *SOAT1*. The asterisks represented the statistical *p*-value (**p* < 0.05, ***p* <
40 0.01, ****p* < 0.001, *****p* < 0.0001).

41

42 **Figure S7** (A) RT-qPCR was used to determine the expression levels of *ETS1* in OSCC
43 and paracancerous tissues (n=30). (B) Western Blot explores the effects of different
44 concentrations of Polyphyllin I on the expression of *ETS1* and *SOAT1* in Cal27 cells
45 after 48 h of treatment. (C) Western Blot was designed to test for changes in the
46 expression of *ETS1* and *SOAT1* in PPI-treated Vector/oeETS1 Cal27 cells for 48 h. (D-
47 E) IHC analysis of *ETS1* and *SOAT1* in 30 pairs of clinical samples of OSCC paired
48 with adjacent tissue. (F-G) The expression levels of downstream lipid metabolism
49 genes in OSCC cells with *ETS1*-overexpressing were checked using RT-qPCR and
50 Western Blot. The asterisks represented the statistical *p*-value (**p* < 0.05, ***p* < 0.01,
51 ****p* < 0.001, *****p* < 0.0001).

52

53 **Figure S8** Schematic diagram of nude mice treatment.

54

55